Hagit Eldar-Finkelman - Publications

Tel Aviv University, Tel Aviv-Yafo, Tel Aviv District, Israel 

49 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Grieco SF, Cheng Y, Eldar-Finkelman H, Jope RS, Beurel E. Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 27542584 DOI: 10.1016/j.pnpbp.2016.08.008  0.32
2015 Aloni E, Shapira M, Eldar-Finkelman H, Barnea A. GSK-3β Inhibition Affects Singing Behavior and Neurogenesis in Adult Songbirds. Brain, Behavior and Evolution. 85: 233-44. PMID 26065821 DOI: 10.1159/000382029  0.32
2014 Azoulay-Alfaguter I, Elya R, Avrahami L, Katz A, Eldar-Finkelman H. Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. Oncogene. PMID 25500539 DOI: 10.1038/onc.2014.390  0.32
2013 La Pietra V, La Regina G, Coluccia A, Famiglini V, Pelliccia S, Plotkin B, Eldar-Finkelman H, Brancale A, Ballatore C, Crowe A, Brunden KR, Marinelli L, Novellino E, Silvestri R. Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors. Journal of Medicinal Chemistry. 56: 10066-78. PMID 24295046 DOI: 10.1021/jm401466v  0.32
2013 Avrahami L, Eldar-Finkelman H. GSK-3 and lysosomes meet in Alzheimer's disease. Communicative & Integrative Biology. 6: e25179. PMID 23940827 DOI: 10.4161/cib.25179  0.32
2013 Beurel E, Kaidanovich-Beilin O, Yeh WI, Song L, Palomo V, Michalek SM, Woodgett JR, Harrington LE, Eldar-Finkelman H, Martinez A, Jope RS. Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3. Journal of Immunology (Baltimore, Md. : 1950). 190: 5000-11. PMID 23606540 DOI: 10.4049/jimmunol.1203057  0.32
2013 Avrahami L, Licht-Murava A, Eisenstein M, Eldar-Finkelman H. GSK-3 inhibition: achieving moderate efficacy with high selectivity. Biochimica Et Biophysica Acta. 1834: 1410-4. PMID 23369789 DOI: 10.1016/j.bbapap.2013.01.016  0.32
2013 Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. The Journal of Biological Chemistry. 288: 1295-306. PMID 23155049 DOI: 10.1074/jbc.M112.409250  0.32
2013 Lo Monte F, Kramer T, Gu J, Brodrecht M, Pilakowski J, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B. Structure-based optimization of oxadiazole-based GSK-3 inhibitors. European Journal of Medicinal Chemistry. 61: 26-40. PMID 22749643 DOI: 10.1016/j.ejmech.2012.06.006  0.32
2012 Licht-Murava A, Eldar-Finkelman H. Exploiting substrate recognition for selective inhibition of protein kinases. Current Pharmaceutical Design. 18: 2914-20. PMID 22571660  0.32
2012 Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α. Journal of Medicinal Chemistry. 55: 4407-24. PMID 22533818 DOI: 10.1021/jm300309a  0.32
2011 Monte FL, Kramer T, Boländer A, Plotkin B, Eldar-Finkelman H, Fuertes A, Dominguez J, Schmidt B. Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas. Bioorganic & Medicinal Chemistry Letters. 21: 5610-5. PMID 21807510 DOI: 10.1016/j.bmcl.2011.06.131  0.32
2011 Alon LT, Pietrokovski S, Barkan S, Avrahami L, Kaidanovich-Beilin O, Woodgett JR, Barnea A, Eldar-Finkelman H. Selective loss of glycogen synthase kinase-3α in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation. Febs Letters. 585: 1158-62. PMID 21419127 DOI: 10.1016/j.febslet.2011.03.025  0.32
2011 Licht-Murava A, Plotkin B, Eisenstein M, Eldar-Finkelman H. Elucidating substrate and inhibitor binding sites on the surface of GSK-3β and the refinement of a competitive inhibitor. Journal of Molecular Biology. 408: 366-78. PMID 21354422 DOI: 10.1016/j.jmb.2011.02.036  0.32
2011 Azoulay-Alfaguter I, Yaffe Y, Licht-Murava A, Urbanska M, Jaworski J, Pietrokovski S, Hirschberg K, Eldar-Finkelman H. Distinct molecular regulation of glycogen synthase kinase-3alpha isozyme controlled by its N-terminal region: functional role in calcium/calpain signaling. The Journal of Biological Chemistry. 286: 13470-80. PMID 21266584 DOI: 10.1074/jbc.M110.127969  0.32
2011 Shruster A, Eldar-Finkelman H, Melamed E, Offen D. Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid β-peptide. Journal of Neurochemistry. 116: 522-9. PMID 21138436 DOI: 10.1111/j.1471-4159.2010.07131.x  0.32
2010 Leng S, Zhang W, Zheng Y, Liberman Z, Rhodes CJ, Eldar-Finkelman H, Sun XJ. Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1. The Journal of Endocrinology. 206: 171-81. PMID 20466847 DOI: 10.1677/JOE-09-0456  0.32
2010 Watson RL, Spalding AC, Zielske SP, Morgan M, Kim AC, Bommer GT, Eldar-Finkelman H, Giordano T, Fearon ER, Hammer GD, Lawrence TS, Ben-Josef E. GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. Neoplasia (New York, N.Y.). 12: 357-65. PMID 20454507 DOI: 10.1593/neo.92112  0.32
2010 Eldar-Finkelman H, Licht-Murava A, Pietrokovski S, Eisenstein M. Substrate competitive GSK-3 inhibitors - strategy and implications. Biochimica Et Biophysica Acta. 1804: 598-603. PMID 19770076 DOI: 10.1016/j.bbapap.2009.09.010  0.32
2009 Eldar-Finkelman H, Eisenstein M. Peptide inhibitors targeting protein kinases. Current Pharmaceutical Design. 15: 2463-70. PMID 19601843 DOI: 10.2174/138161209788682253  0.32
2008 Ilouz R, Pietrokovski S, Eisenstein M, Eldar-Finkelman H. New insights into the autoinhibition mechanism of glycogen synthase kinase-3beta. Journal of Molecular Biology. 383: 999-1007. PMID 18793648 DOI: 10.1016/j.jmb.2008.08.079  0.32
2008 Liberman Z, Plotkin B, Tennenbaum T, Eldar-Finkelman H. Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C betaII in the diabetic fat tissue. American Journal of Physiology. Endocrinology and Metabolism. 294: E1169-77. PMID 18430969 DOI: 10.1152/ajpendo.00050.2008  0.32
2008 Caspi M, Zilberberg A, Eldar-Finkelman H, Rosin-Arbesfeld R. Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner. Oncogene. 27: 3546-55. PMID 18223684 DOI: 10.1038/sj.onc.1211026  0.32
2008 Sharfi H, Eldar-Finkelman H. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. American Journal of Physiology. Endocrinology and Metabolism. 294: E307-15. PMID 18029441 DOI: 10.1152/ajpendo.00534.2007  0.32
2007 Erez A, Castiel A, Trakhtenbrot L, Perelman M, Rosenthal E, Goldstein I, Stettner N, Harmelin A, Eldar-Finkelman H, Campaner S, Kirsch I, Izraeli S. The SIL gene is essential for mitotic entry and survival of cancer cells. Cancer Research. 67: 4022-7. PMID 17456584 DOI: 10.1158/0008-5472.CAN-07-0064  0.32
2007 Shapira M, Licht A, Milman A, Pick CG, Shohami E, Eldar-Finkelman H. Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury. Molecular and Cellular Neurosciences. 34: 571-7. PMID 17289399 DOI: 10.1016/j.mcn.2006.12.006  0.32
2006 Kaidanovich-Beilin O, Eldar-Finkelman H. Peptides targeting protein kinases: strategies and implications. Physiology (Bethesda, Md.). 21: 411-8. PMID 17119154 DOI: 10.1152/physiol.00022.2006  0.32
2006 Ilouz R, Kowalsman N, Eisenstein M, Eldar-Finkelman H. Identification of novel glycogen synthase kinase-3beta substrate-interacting residues suggests a common mechanism for substrate recognition. The Journal of Biological Chemistry. 281: 30621-30. PMID 16893889 DOI: 10.1074/jbc.M604633200  0.32
2006 Kaidanovich-Beilin O, Eldar-Finkelman H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. The Journal of Pharmacology and Experimental Therapeutics. 316: 17-24. PMID 16169938 DOI: 10.1124/jpet.105.090266  0.32
2006 Eldar-Finkelman H. Editorial Current Drug Targets. 7: 1375.  0.32
2005 Liberman Z, Eldar-Finkelman H. Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. The Journal of Biological Chemistry. 280: 4422-8. PMID 15574412 DOI: 10.1074/jbc.M410610200  0.32
2005 Talior I, Tennenbaum T, Kuroki T, Eldar-Finkelman H. PKC-delta-dependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice: role for NADPH oxidase. American Journal of Physiology. Endocrinology and Metabolism. 288: E405-11. PMID 15507533 DOI: 10.1152/ajpendo.00378.2004  0.32
2004 Kirshenboim N, Plotkin B, Shlomo SB, Kaidanovich-Beilin O, Eldar-Finkelman H. Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha. Journal of Molecular Neuroscience : Mn. 24: 237-45. PMID 15456937 DOI: 10.1385/JMN:24:2:237  0.32
2004 Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biological Psychiatry. 55: 781-4. PMID 15050857 DOI: 10.1016/j.biopsych.2004.01.008  0.32
2003 Eldar-Finkelman H, Ilouz R. Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment. Expert Opinion On Investigational Drugs. 12: 1511-9. PMID 12943495 DOI: 10.1517/13543784.12.9.1511  0.32
2003 Talior I, Yarkoni M, Bashan N, Eldar-Finkelman H. Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice. American Journal of Physiology. Endocrinology and Metabolism. 285: E295-302. PMID 12857675 DOI: 10.1152/ajpendo.00044.2003  0.32
2003 Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. The Journal of Pharmacology and Experimental Therapeutics. 305: 974-80. PMID 12626660 DOI: 10.1124/jpet.102.047381  0.32
2002 Kaidanovich O, Eldar-Finkelman H. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opinion On Therapeutic Targets. 6: 555-61. PMID 12387679 DOI: 10.1517/14728222.6.5.555  0.32
2002 Ilouz R, Kaidanovich O, Gurwitz D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochemical and Biophysical Research Communications. 295: 102-6. PMID 12083774 DOI: 10.1016/S0006-291X(02)00636-8  0.32
2002 Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends in Molecular Medicine. 8: 126-32. PMID 11879773 DOI: 10.1016/S1471-4914(01)02266-3  0.32
2001 Gurwitz D, Eldar-Finkelman H. Monitor and Molecules. Drug Discovery Today. 6: 1072-1073. PMID 11590039  0.32
2001 Hall JL, Chatham JC, Eldar-Finkelman H, Gibbons GH. Upregulation of glucose metabolism during intimal lesion formation is coupled to the inhibition of vascular smooth muscle cell apoptosis. Role of GSK3beta. Diabetes. 50: 1171-9. PMID 11334423  0.32
2000 Zhao AZ, Shinohara MM, Huang D, Shimizu M, Eldar-Finkelman H, Krebs EG, Beavo JA, Bornfeldt KE. Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. The Journal of Biological Chemistry. 275: 11348-54. PMID 10753948 DOI: 10.1074/jbc.275.15.11348  0.32
1999 Eldar-Finkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC, Krebs EG. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes. 48: 1662-6. PMID 10426388 DOI: 10.2337/diabetes.48.8.1662  0.32
1999 Torres MA, Eldar-Finkelman H, Krebs EG, Moon RT. Regulation of ribosomal S6 protein kinase-p90(rsk), glycogen synthase kinase 3, and beta-catenin in early Xenopus development. Molecular and Cellular Biology. 19: 1427-37. PMID 9891076  0.32
1997 Eldar-Finkelman H, Krebs EG. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proceedings of the National Academy of Sciences of the United States of America. 94: 9660-4. PMID 9275179 DOI: 10.1073/pnas.94.18.9660  0.32
1996 Eldar-Finkelman H, Argast GM, Foord O, Fischer EH, Krebs EG. Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells. Proceedings of the National Academy of Sciences of the United States of America. 93: 10228-33. PMID 8816781 DOI: 10.1073/pnas.93.19.10228  0.32
1995 Eldar-Finkelman H, Seger R, Vandenheede JR, Krebs EG. Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. The Journal of Biological Chemistry. 270: 987-90. PMID 7836418 DOI: 10.1074/jbc.270.3.987  0.32
1994 Seger R, Seger D, Reszka AA, Munar ES, Eldar-Finkelman H, Dobrowolska G, Jensen AM, Campbell JS, Fischer EH, Krebs EG. Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. The Journal of Biological Chemistry. 269: 25699-709. PMID 7929275  0.32
Show low-probability matches.